<DOC>
	<DOCNO>NCT02315872</DOCNO>
	<brief_summary>This study Acthar gel ( ACTH ) patient relapse multiple sclerosis experience chronic fatigue .</brief_summary>
	<brief_title>ACTH Fatigue Multiple Sclerosis Patients</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled study demonstrate safety , tolerability , effect ACTH fatigue patient relapse multiple sclerosis ( RMS ) . The primary objective study assess efficacy ACTH versus placebo reduce fatigability patient RMS . Secondary objective include assessment tolerability safety twice-weekly ACTH treatment vs. placebo evaluation ACTH depression , sleepiness , quality life measure correlation measure .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Have document diagnosis Relapsing MS define McDonald Criteria 2011 Revision least 6 month Have treat interferon beta 1a 1b , glatiramer acetate , fingolimod , dimethyl fumarate , teriflunomide least 6 month , report adherence rate least 75 % , time screen Have Kurtzke Expanded Disability Status Scale ( EDSS ) score 0 4 , inclusive Have MFIS ≥ 38 FSS ≥ 36 , BDIII great equal 19 , ESS great equal 9 Women childbearing potential must employ proven method prevent pregnancy course trial Able understand purpose risk study Must willing sign inform consent Must willing follow protocol requirement Subject must agree receive live liveattenuated vaccine trial Have contraindication Acthar Gel list approved label , include sensitivity protein porcine origin . Had treatment systemic oral corticosteroid type 90 day prior baseline/randomization Had relapse document objective neurologic worsen 90 day prior baseline/randomization Has concurrent neurological disease multiple sclerosis History sleep apnea History ( within 90 day ) nocturnal pain / nocturnal spasm interfere disrupts sleep , uncontrolled nocturnal restless leg syndrome History psychosis , bipolar disorder , mania/hypomania History coronary heart disease , congestive heart failure , chronic pulmonary disease , emphysema , anemia , bleed disorder , gastrointestinal bleeding , intestinal ulcer , clinically significant cardiac arrhythmia , Type I II diabetes , uncontrolled hypertension , seizure disorder , cardiac arrhythmia , immune deficiency disorder , HIVAIDS , tuberculosis , dysthyroidal state ( patient history hypothyroidism hyperthyroidism , correct physiological level exclude ) History substance abuse , tobacco within past 5 year current alcohol dependence Current use cannabis , opiates , benzodiazepine , barbiturate , gabapentin , pregabalin , topiramate , divalproex sodium , carbamazepine , oxcarbazepine , gabaergic medication tizanidine Baclofen , permit spasticity treatment History malignant neoplasm except past basal cell squamous cell carcinoma skin , successfully treat prior screen visit History psychosis history use neuroleptic include , restrict , haloperidol , chlorpromazine , aripiprazole , olanzapine , risperidone History suicide attempt , current suicidal think prepare suicide Current use Amphetamines methylphenidate Current use modafinil , armodafinil Current use amantidine The subject must medicationfree interval : . 7 day prior use : i. methylphenidate , amphetamine dextroamphetamine ii . modafinil armodafinil iii . diphenhydramine , phenylephrine , loratadine iv . gabapentin , pregabalin , topiramate , valproate/divalproex v. oxcarbazepine vi . codeine , hydrocodone , oxycodone , diphenhydramine , phenylephrine , gabapentin , pregabalin , topiramate , valproate/divalproex , oxcarbazepine , codeine , hydrocodone , oxycodone b . 14 day prior use : i. desloratadine ii . Amantidine iii . alprazolam , lorazepam , morphine , hydromorphone , amantidine , alprazolam , lorazepam iv . morphine , hydromorphone c. 28 day prior use : i. clonazepam ii . cannabis cannabinoids d. 90 day prior use carbamazepine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Acthar Gel</keyword>
	<keyword>ACTH</keyword>
	<keyword>Fatigue</keyword>
</DOC>